However, H3R-specific compounds have shown mixed results in treating cognitive impairment associated with schizophrenia in clinical trials (Vohora and Bhowmik, 2012; Egan et al., 2013; Haig et al., 2014; Jarskog et al., 2015). This evidence concerns the gene HRH3 and schizophrenia.